
On May 26, 2026, the VA announced a clinical trial to test MDMA-assisted therapy for veterans battling PTSD and alcohol use disorder. The study, which began enrollment quietly on May 18, is one of 19 psychedelic trials the VA is funding through $23 million in external grants, enrolling approximately 80 veterans at facilities in Providence, Rhode Island, and West Haven, Connecticut, with results expected in May 2030.
The trial will study the safety and effectiveness of MDMA-assisted therapy to address conditions that do not fully respond to standard treatments. For those living with traumatic brain injury, the treatment’s benefit may be significant. Research shows that patients with head injuries are more likely to develop PTSD than those without a TBI history. Studies confirm that veterans with probable TBI have 1.72 times greater odds of developing PTSD.
“This trial represents an important step in safely evaluating new approaches and innovations to treat Veterans with severe mental health conditions,” said VA Secretary Doug Collins. For the hundreds of thousands of veterans carrying both a damaged brain and a traumatized mind, it may represent something even more profound: a second chance at healing.





